BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 19700194)

  • 1. Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study.
    Nguyen QD; Shah SM; Heier JS; Do DV; Lim J; Boyer D; Abraham P; Campochiaro PA;
    Ophthalmology; 2009 Nov; 116(11):2175-81.e1. PubMed ID: 19700194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment.
    Do DV; Nguyen QD; Khwaja AA; Channa R; Sepah YJ; Sophie R; Hafiz G; Campochiaro PA;
    JAMA Ophthalmol; 2013 Feb; 131(2):139-45. PubMed ID: 23544200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.
    ; Elman MJ; Aiello LP; Beck RW; Bressler NM; Bressler SB; Edwards AR; Ferris FL; Friedman SM; Glassman AR; Miller KM; Scott IU; Stockdale CR; Sun JK
    Ophthalmology; 2010 Jun; 117(6):1064-1077.e35. PubMed ID: 20427088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial.
    Brown DM; Ou WC; Wong TP; Kim RY; Croft DE; Wykoff CC;
    Ophthalmology; 2018 May; 125(5):683-690. PubMed ID: 29336896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The REVEAL Study: Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Asian Patients with Diabetic Macular Edema.
    Ishibashi T; Li X; Koh A; Lai TY; Lee FL; Lee WK; Ma Z; Ohji M; Tan N; Cha SB; Shamsazar J; Yau CL;
    Ophthalmology; 2015 Jul; 122(7):1402-15. PubMed ID: 25983216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results.
    Elman MJ; Ayala A; Bressler NM; Browning D; Flaxel CJ; Glassman AR; Jampol LM; Stone TW;
    Ophthalmology; 2015 Feb; 122(2):375-81. PubMed ID: 25439614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results.
    ; Elman MJ; Qin H; Aiello LP; Beck RW; Bressler NM; Ferris FL; Glassman AR; Maturi RK; Melia M
    Ophthalmology; 2012 Nov; 119(11):2312-8. PubMed ID: 22999634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.
    Mitchell P; Bandello F; Schmidt-Erfurth U; Lang GE; Massin P; Schlingemann RO; Sutter F; Simader C; Burian G; Gerstner O; Weichselberger A;
    Ophthalmology; 2011 Apr; 118(4):615-25. PubMed ID: 21459215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.
    Elman MJ; Bressler NM; Qin H; Beck RW; Ferris FL; Friedman SM; Glassman AR; Scott IU; Stockdale CR; Sun JK;
    Ophthalmology; 2011 Apr; 118(4):609-14. PubMed ID: 21459214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy/safety of ranibizumab monotherapy or with laser versus laser monotherapy in DME.
    Berger A; Sheidow T; Cruess AF; Arbour JD; Courseau AS; de Takacsy F
    Can J Ophthalmol; 2015 Jun; 50(3):209-16. PubMed ID: 26040221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
    Solaiman KA; Diab MM; Abo-Elenin M
    Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study).
    Comyn O; Sivaprasad S; Peto T; Neveu MM; Holder GE; Xing W; Bunce CV; Patel PJ; Egan CA; Bainbridge JW; Hykin PG
    Am J Ophthalmol; 2014 May; 157(5):960-70. PubMed ID: 24531025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: six-month outcomes.
    Lam DS; Chan CK; Mohamed S; Lai TY; Lee VY; Liu DT; Li KK; Li PS; Shanmugam MP
    Ophthalmology; 2007 Dec; 114(12):2162-7. PubMed ID: 17459479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results.
    Payne JF; Wykoff CC; Clark WL; Bruce BB; Boyer DS; Brown DM;
    Br J Ophthalmol; 2021 Feb; 105(2):253-257. PubMed ID: 32303499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.
    Michaelides M; Kaines A; Hamilton RD; Fraser-Bell S; Rajendram R; Quhill F; Boos CJ; Xing W; Egan C; Peto T; Bunce C; Leslie RD; Hykin PG
    Ophthalmology; 2010 Jun; 117(6):1078-1086.e2. PubMed ID: 20416952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab.
    Channa R; Sophie R; Khwaja AA; Do DV; Hafiz G; Nguyen QD; Campochiaro PA;
    Eye (Lond); 2014 Mar; 28(3):269-78. PubMed ID: 24263379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.
    Campochiaro PA; Heier JS; Feiner L; Gray S; Saroj N; Rundle AC; Murahashi WY; Rubio RG;
    Ophthalmology; 2010 Jun; 117(6):1102-1112.e1. PubMed ID: 20398941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 Year Outcomes.
    Payne JF; Wykoff CC; Clark WL; Bruce BB; Boyer DS; Brown DM;
    Ophthalmology; 2017 Jan; 124(1):74-81. PubMed ID: 27836430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study.
    Pearce I; Banerjee S; Burton BJ; Chakravarthy U; Downey L; Gale RP; Gibson J; Pagliarini S; Patel J; Sivaprasad S; Andrews C; Brittain C; Warburton J;
    Ophthalmology; 2015 Sep; 122(9):1811-9. PubMed ID: 26150052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal ranibizumab alone or in combination with panretinal photocoagulation for the treatment of proliferative diabetic retinopathy with coexistent macular edema: long-term outcomes of a prospective study.
    Chatziralli I; Dimitriou E; Theodossiadis G; Kazantzis D; Theodossiadis P
    Acta Diabetol; 2020 Oct; 57(10):1219-1225. PubMed ID: 32472172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.